1330.8000 18.50 (1.41%)
NSE Dec 29, 2025 15:31 PM
Volume: 41,366
 

1330.80
1.41%
Deven Choksey
Tatva Chintan is transitioning into a stronger growth phase primarily driven by SDA recovery, clearer electrolyte-salt commercialization, scalable agro/pharma pipelines, and a structurally high-entry-barrier semiconductor opportunity.
Tatva Chintan Pharma has gained 54.89% in the last 1 Year
More from Tatva Chintan Pharma Chem Ltd.
Recommended